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levels at or above 0.3% of total fatty acids and visual func-
tion at 12 months in formula-fed infants, and also in 
breastfed infants receiving such formulae after weaning 
 [3] . EFSA concluded that the wording ‘DHA contributes 
to the visual development of infants’ reflects the scientific 
evidence but should be restricted to formulae that contain 
at least 0.3% of the total fatty acids as DHA. 
 While this seemed like a straightforward case based 
on adequate scientific data, an activist group in the Unit-
ed Kingdom embarked on active lobbying against the 
adoption of this health claim, apparently driven by the 
conviction that no infant food should bear health claims. 
The activist group convinced some members of the Eu-
ropean Parliament to support its cause and to propose the 
cited resolution, which has adopted a number of pseudo-
scientific arguments of the activists, unfortunately with-
out critical evaluation of their validity.
 The adopted resolution reports that scientific evidence 
shows a benefit of DHA in breast milk for the visual de-
velopment of infants, whereas such effects of DHA in for-
mula had not been demonstrated. To support this conclu-
sion, one single systematic review is cited which states that 
there would be no conclusive evidence for benefits of add-
ing the   -3 fatty acid DHA to infant formulae, although 
the authors acknowledged that some studies found ben-
efits on visual function  [4] . However, in contrast to the 
EFSA analysis, these authors did not consider the amount 
of DHA added to formula as a predictor of outcome.
 On March 16, 2011, a slight majority of members of
the European Parliament’s Committee on Environment, 
Public Health and Food Safety adopted a resolution aim-
ing at the refusal of authorising a health claim on infant 
foods (30 votes in favour, 28 against, 1 abstention)  [1] . 
This resolution opposes the adoption of the health claim 
‘Docosahexaenoic acid (DHA) intake contributes to the 
normal visual development of infants up to 12 months of 
age’, which had been recommended for adoption by both 
the European Commission and the Standing Committee 
on Food of the European Member States. Following this 
committee vote, the European Parliament’s plenary will 
now have to take a decision in the near future as to wheth-
er it supports or rejects the adoption of this health claim. 
 How did this amazing controversy evolve? The Euro-
pean regulation on health claims for foods stipulates that 
these should be truthful and based on generally accepted 
scientific evidence of the relationship between diet and 
health  [2] . Scientific substantiation should be the main 
aspect to be taken into account for the use of nutrition and 
health claims, and it should be based on the totality of 
available scientific data  [2] . The European Food Safety 
Authority (EFSA) has been charged to perform this scien-
tific evaluation, with the help of qualified scientists. In the 
current case, EFSA has reviewed the available evidence. It 
concluded that a cause and effect relationship is estab-
lished between the intake of infant and follow-on formu-
lae supplemented with docosahexaenoic acid (DHA) at 
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 EFSA based its conclusions on this question not on a 
single, selected publication, but reviewed the totality of 
available data with the required scientific accuracy. EFSA 
evaluated 43 relevant scientific publications, including 13 
publications on randomised clinical trials  [3] . The evalu-
ation performed by EFSA is thorough and meets high sci-
entific standards. It is very surprising and disturbing that 
the members of the European Parliament find such a pro-
found scientific evaluation by an independent body less 
convincing than the arguments of a loud-mouthed lob-
bying group.
 The resolution also raises concerns on the safety of 
adding the   -3 fatty acid DHA to infant formulae, bor-
rowing analogous statements of the said activist group. 
This is anomalous since independent from any potential 
health claims, any formula for infants is only suitable for 
marketing in Europe if it is safe for infant feeding  [5] .
European legislation supported by the European Parlia-
ment accepted the optional addition of DHA and other 
long-chain polyunsaturated fatty acids to infant and 
 follow-on formulae as a safe measure  [5] , based on a 
 thorough scientific assessment of its suitability and safety 
by the Scientific Committee on Food  [6] . 
 The resolution raises worries on safety by referring to 
a follow-up study in a subgroup of 10-year-old children 
who had previously participated in an infant feeding 
study  [7] . However, the citation of findings from this 
study is incomplete and misleading. An unbiased evalu-
ation of this study leads to the conclusion that it does not 
at all demonstrate untoward effects of DHA addition to 
infant formulae. The authors revisited a small subgroup 
of 45% of the initial study population at the age of 10 
years. The considerable attrition with a high potential for 
selection bias obviously limits the conclusions that can 
be drawn with respect to long-term effects of early feed-
ing. Moreover, the study did not find any group differ-
ences for growth in the total study population, and 
among boys. The small group of 25 examined girls, who 
as infants had received an infant formula with DHA, was 
significantly taller at the age of 10 years (by about 4 cm) 
than the group of girls who had received a control for-
mula without DHA. The taller group of girls also had a 
proportionally higher body weight, whereas the body 
mass index was not different. As one would expect, also 
the mean blood pressure was slightly higher in the girls 
with a larger body size, which reflects the fundamental 
laws of physics: larger people have a higher blood pres-
sure. Of importance, these evaluations represent a sec-
ondary subgroup data analysis deviating from the origi-
nal study hypothesis. Therefore, these analyses do not 
have the power to demonstrate a causal relationship to 
the type of feeding provided in infancy. If one would 
wish to construct such a relation, one would actually 
have to conclude that DHA supply of infant formulae had 
a beneficial effect on length growth and not untoward 
effects. 
 Furthermore, the adopted resolution does not reveal 
that a systematic review and meta-analysis of a large 
number of controlled trials showed no effects of DHA 
enrichment of infant formulae on child growth  [8] . Also, 
it does not refer to a follow-up study in children that had 
previously received infant formula with or without DHA 
 [9] . Children in the DHA group did not differ in growth 
but showed a beneficial blood pressure-lowering effect at 
early school age. The rather selective presentation of data 
in the draft resolution is very disturbing since it does not 
facilitate a balanced and rational judgement by the mem-
bers of parliament.
 The resolution proposes that there would be no scien-
tific agreement on the usefulness of providing the   -3 
fatty acid DHA with food products for infants. This sug-
gestion is in stark contrast to numerous national and 
 international recommendations that uniformly recom-
mend a DHA supply to infants and are supported i.e. by 
the World Health Organisation, the Food and Agricul-
ture Organisation of the United Nations, the World As-
sociation of Perinatal Medicine, the Child Health Foun-
dation, the Diabetic Pregnancy Study Group, the Early 
Nutrition Academy, the European Association of Perina-
tal Medicine, the European Society for Clinical Nutrition 
and Metabolism, the European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition, the Inter-
national Federation of Placenta Associations, the Inter-
national Society for the Study of Fatty Acids and Lipids, 
and the French Food Safety Authority AFFSA. 
 Perhaps one might question whether there should be 
any health claims made for infant food products, since 
breastfeeding is clearly considered the optimal form of 
infant feeding which therefore must be strongly protect-
ed, promoted and supported  [10] . However, not all infants 
are fully breastfed during the first half year of life and 
partially breastfed thereafter. For these infants, safe in-
fant formulae of the highest possible quality are required, 
and health care professionals and families should be able 
to receive appropriate information on their characteris-
tics  [11] . European legislation supports that relevant sci-
ence-based product properties can be declared for formu-
lae for infants to allow for a selection of appropriate prod-
ucts by physicians, other health care professionals and 
families, given they are based on a properly scrutinised 
 Health Claims: Let Science Prevail
 
Ann Nutr Metab 2011;58:79–81 81
scientific basis (e.g. properties such as lactose free, hy-
poallergenic)  [5] . In the European Union, EFSA has been 
charged with examining the scientific basis of potential 
further product claims, which EFSA performs with high 
scientific thoroughness applying very strict standards. 
Clearly, any decisions on the authorisation of health 
claims for food products for infants should be based on 
such a meticulous, medical-scientific evaluation and not 
on biased lobbying of activist groups.
 Preventing communication of scientifically assured 
benefits of optimised products bears the risk that it may 
slow or even stop the significant quality improvements of 
foods for infants that has occurred over the last decades 
in numerous single steps, and which has led to large ben-
efits for child health. In the future, manufacturers might 
not be willing any more to invest major resources into the 
development, clinical evaluation and implementation of 
further improvements, if there is no chance to communi-
cate such improvements. Such a development may con-
siderably compromise the further optimisation of infant 
nutrition which is so necessary for further improving 
child health. Therefore, it is truly important that science 
and not lobbying prevails in this matter.
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European Parliament vote on Health Claim for Baby Foods
Proposals to allow producers to claim that adding the fatty acid DHA to baby 
food ‘contributes to the normal visual developments of infants up to 12 months 
of age’ were backed by the European Parliament on April 6, 2011. The resolution 
opposing the plan did not achieve the majority of votes required (328 for, 323 
against and 26 abstentions) and is therefore rejected.
http://www.europarl.europa.eu/en/pressroom/content/20110406IPR17110/html/
DHA-in-baby-food-European-Parliament-approves-health-claim 
